2023 INTERIM RESULTS CONFERENCE CALL

TREATING PATIENTS BEYOND BORDERS

AUGUST 2023

Antengene's Speakers Today

Jay Mei, M.D., Ph.D. – Founder, Chairman and Chief Executive Officer

Amily Zhang, M.D. – Chief Medical Officer

John F. Chin, MBA – Chief Business Officer

Donald Lung, J.D., MBA – Chief Financial Officer

Bo Shan, Ph.D. – Chief Scientific Officer

Kavin Cao, CFA – Executive Director, Board Secretary and Corporate Finance & Investor Relations Director

Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following:

The information in this presentation has been prepared by representatives of Antengene Corporation Limited (the "Company" and, together with its subsidiaries, the "Group") for use in presentations by the Group for information purpose. No part of this presentation will form the basis of, or be relied on in connection with, any contract or commitment or investment decision.

Certain statements contained in this presentation and in the accompanying oral presentation, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding investigational drug candidates and clinical trials and the status and related results thereto, as well as those regarding continuing and further development and commercialization efforts and transactions with third parties. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the global and regional regulatory environment in the jurisdictions in which the Company's does business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational drug candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company's current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of the Company's drug candidates, final and quality controlled verification of data and the related analyses, the expense and uncertainty of obtaining regulatory approval, the possibility of having to conduct additional clinical trials and the Company's reliance on third parties to conduct drug development, manufacturing and other services. Further, even if regulatory approval is obtained, pharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company's prospectus published onto the websites of the Company and The Stock Exchange of Hong Kong Limited and the announcements and other disclosures we make from time to time. The reader should not place undue reliance on any forward-looking statements included in this presentation or in the accompanying oral presentation. These statements speak only as of the date made, and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believe," "expects," "may," "will," "could," "should," "shall," "risk," "intends," "estimates," "plans," "predicts," "continues," "assumes," "positioned" or "anticipates" or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The information set out herein may be subject to updating, revision, verification and amendment and such information may change materially.

This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in any jurisdiction which prohibits the same except in compliance with applicable securities laws. This presentation and the accompanying oral presentation contains data and information obtained from third-party studies and internal company analysis of such data and information. We have not independently verified the data and information obtained from these sources.

By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

2023 1H OVERVIEW

ANTENGENE

Antengene is Executing on Our Strategy to Bring Transformative Medicines to Patients Around the World



Regions in Antengene Markets where XPOVIO® is Approved

Regions with Ongoing Clinical Trials

Commercialization in

6 APAC Markets

9 Clinical Stage Assets

15 Ongoing Trials

in the Mainland of China, Australia and the US

Navigating Forward: Milestones Achieved in 2023 YTD, Shaping a Pivotal Transition Year for Our R&D Pipeline

ANTENGENE

Research and Development

9 Clinical Stage Assets

4 Clinical Development Partnerships

Bristol Myers Squibb · MERCK · BeiGene · 君实生物 TopAlliance

6 Research Data Publications

2023 ASCO ANNUAL MEETING · AACR American Association for Cancer Research ANNUAL MEETING 2023 Orlando

APAC R&D

ATG-008 (Onatasertib) – mTORC1/2 Inhibitor

Achievements To Date

- ✓ **Data presentation** of "TORCH-2" trial cervical cancer data at **ASCO 2023** *(based on a previous data cut)*
- ✓ Progressing smoothly in the "TORCH-2" trial with **updated encouraging periodic data*** in the cervical cancer cohort **(Data as of August 23rd, 2023)**
  - **ORR** of **46.4%** (13/28) in **CPI-naïve** R/R cervical cancer
  - **ORR** of **26.7%** (4/15) in **CPI-treated** R/R cervical cancer
  - **mPFS** of **7.20 months** among **efficacy-evaluable population** in **CPI-naïve** R/R cervical cancer

2023 Catalysts

- ○ Confirm the **regulatory pathway** for ATG-008 in combination anti-PD-1 monoclonal antibody in **relapsed/metastatic cervical cancer**
- ○ **Full data readout for the CPI-naïve cervical cancer cohort of "TORCH-2" trial** during the Antengene **R&D Day** in **November**

GLOBAL R&D

Achievements To Date

- ✓ Received **US FDA IND clearance** for the first-in-class **anti-CD24 mAb** ATG-031, and selected the **MD Anderson Cancer Center** in Houston, Texas as the leading site for this clinical trial
- ✓ **Initiated the Phase I trial** for ATG-022 (**Claudin 18.2** ADC) and **a partial response has already been observed**
- ✓ ATG-101 (**PD-L1/4-1BB** BsAb) is approaching **biologically active dose** with **good tolerability, partial response, and durable stable disease**
- ✓ ATG-018 (**ATR** inhibitor) is making smooth progress through dose escalation; **7 out of 12** efficacy evaluable patients at **low dose levels** are with **stable disease**
- ✓ Reached **RP2D for monotherapy** and dosed the first patient in the United States in the **nivolumab combination portion** of the clinical study evaluating ATG-017 Tizaterkib (**ERK1/2** inhibitor) in patients with advanced solid tumors
- ✓ **13 patients** in the Phase I trial evaluating ATG-037 (**CD73** inhibitor) in patients with advanced solid tumors are undergoing the optional **combination dose escalation with pembrolizumab**

2023 Catalysts

- ○ **Updated clinical data** will be presented during the Antengene **R&D Day** in **November**

XPOVIO® R&D and Pan-APAC Commercialization

2023 1H Revenue: RMB72.0 Million

(+33.5% vs 2022 1H Revenue of RMB 54.0 mm)

6 Approved Markets: Hong Kong, Taiwan

Entered into a Commercialization Partnership with 翰森製藥 HANSOH PHARMA in the Mainland of China on August 11th

Achievements To Date

- ✓ **XVd regimen** in 2L+ MM achieving reimbursement listing in Australia
- ✓ **XVd regimen** in 2L+ MM and **Xd regimen** in R/R MM included in the Singaporean Cancer Drug List
- ✓ **Complete patient enrollment** for **"BENCH"** study in 2L+ MM
- ✓ NDA approval in **Hong Kong**
- ✓ **sNDA filing in Hong Kong** for SVd regimen in MM and S monotherapy in DLBCL
- ✓ **NDA filing in Indonesia** for SVd and Sd regimen in MM and S monotherapy in DLBCL

2023 Catalysts

- ○ **sNDA submission** in **the Mainland of China** for **"SEARCH" study** in **R/R DLBCL**
- ○ **Xd regimen** in R/R MM achieving reimbursement listing in South Korea

CLINICAL OVERVIEW

ANTENGENE

ANTENGENE

APAC RIGHTS ASSETS

APAC Rights Assets: Pipeline of Commercial or Near NDA Stage Drugs with First-in-Class/Best-in-Class Potentials

ANTENGENE

Assets	Target *(Modality)*	Indication	Pre-clinical / Phase I / Phase II / Phase III/Pivotal / NDA / Commercialization	Antengene Rights	Partner
ATG-010[1] (Selinexor)	**XPO1** *(Small molecule)*	R/R Multiple Myeloma	Combo with dexamethasone *(MARCH)* — *The Mainland of China NDA approved*	APAC[2]	Karyopharm Therapeutics
			Combo with dexamethasone *(STORM) – Partner's Pivotal Trial in the US* — *US, EU, SK, SG, AU, TW & HK NDA approved*		
			Combo with bortezomib and dexamethasone *(BENCH)* ★ — **Enrollment Completed**		
			Combo with bortezomib and dexamethasone *(BOSTON) – Partner's Pivotal Trial in the US* — *US, EU, SG, AU & TW sNDA approved*		
			Combo with IMID/PI/CD38 mAb and dexamethasone *(STOMP)*		
		R/R Diffuse Large B-cell Lymphoma	Monotherapy *(SEARCH)* ★ — **Pre-sNDA Submitted**		
			Monotherapy *(SADAL) – Partner's Pivotal Trial in the US* — *US , SG, SK & TW sNDA approved*		
			Combo with R-GDP *(DLBCL-030)* ★		
		Myelofibrosis	Combo with ruxolitinib *(MF-034)* ★		
		R/R Non-Hodgkin's Lymphoma	Combo with lenalidomide + rituximab *(SWATCH)*		
		R/R T-cell & NK-cell Lymphoma	Combo with ICE/GemOx/tislelizumab *(TOUCH)* with BeiGene		
		Maintenance Therapy for Endometrial Cancer	Monotherapy *(SIENDO)*		
			Monotherapy *(EC-042) – Partner's Pivotal Trial in the US* ★		
ATG-016 (Eltanexor)	**XPO1** *(Small molecule)*	R/R Myelodysplastic Syndromes	Monotherapy *(HATCH)*		
ATG-008 (Onatasertib)	**mTORC1/2** *(Small molecule)*	Cervical Cancer and Other Advanced Solid Tumors	Combo with toripalimab *(TORCH-2)** with 君实生物 TopAlliance	APAC[3]	Celgene / Bristol Myers Squibb Company

Antengene Trials[4] | Partner Trials[5] | Global Trials in Collaboration with Partner | ★ Registrational Trial

[1] (s)NDA approved by US FDA, European Commission, China NMPA, Australia TGA, South Korea MFDS, Singapore HSA, China Hong Kong DoH and China Taiwan TFDA;
[2] Antengene has rights for Greater China (The Mainland of China, Hong Kong, Taiwan, Macau), Australia, New Zealand, South Korea, and the ASEAN Countries;
[3] Antengene has rights for Greater China, South Korea, Singapore, Malaysia, Indonesia, Vietnam, Laos, Cambodia, the Philippines, Thailand and Mongolia;
[4] Most advanced trial status in Antengene territories and the trials are responsible by Antengene;
[5] Most advanced trial status in partner territories in the rest of the world and the trials are conducted by our licensing partners

* Investigator-initiated trials; R/R: relapsed/refractory; ND: newly diagnosed; MDS: myelodysplastic syndrome; CRC: colorectal cancer; PrC: prostate cancer; CAEBV: chronic active Epstein-Barr virus; NHL: non-Hodgkin lymphoma; Hem/Onc: hematological malignancies and solid tumors; R-GDP: Rituximab, Gemcitabine, Dexamethasone & Cisplatin; GemOx: Gemcitabine, Oxaliplatin; ICE: Ifosfamide, Carboplatin, Etoposide

AU: Australia; EU: Europe; SG: Singapore; SK: South Korea; TW: Taiwan; US: United States;

Broad Indication Expansion Potential for XPOVIO®/Selinexor Beyond Multiple Myeloma and Diffuse Large B-cell Lymphoma

ANTENGENE

	Diffuse Large B-cell Lymphoma	Multiple Myeloma	Myelofibrosis	Endometrial Cancer
Incidence	37,100 (China) 6,400 (APAC)	21,000 (China) 6,000 (APAC)	11,000 (China) 1,900 (APAC)	81,900 (China) 10,900 (APAC)
Prevalence	104,220 (China) 16,000 (APAC)	51,000 (China) 23,500 (APAC)	62,000 (China) 8,740 (APAC)	244,800 (China) 64,100 (APAC)
On-going Clinical Trials in China and Globally	**"SEARCH" Study** *China Bridging Study for 3L DLBCL* *Expected sNDA Submission in Q3 2023* **"XPORT-DLBCL-030" Study** *Global Registrational Trial for 2L DLBCL*	**"BENCH" Study** *China Bridging Study for 2L MM* *Expected sNDA Submission in H1 2024*	**"XPORT-MF-034" Study** *Global Registrational Trial for 1L MF*	**"SIENDO" Study** *Global Phase III Trial for Maintenance Therapy of Endometrial Cancer* **"XPORT-EC-042" Study** *Global Registrational Trial for Maintenance Therapy of Endometrial Cancer*

Source: The Global Cancer Observatory, Frost & Sullivan , Global Data, Journal of Diagnostics Concepts & Practice, Chin J Hematol, Journal of Diagnostics Concepts & Practice, Chin J Oncol, European Haematology Association, Chin J Cancer Prev Treat, AIHW, Local cancer registries – NCC South Korea, Taiwan Cancer Registry

** Approved for RRMM by the US FDA, European EMA, Chinese NMPA, Korean MFDS, Singaporean HSA, Australian TGA, Taiwan TFDA, and Hong Kong DoH. Approved for RRDLBCL by the US FDA, Korean MFDS, Singaporean HSA, and Taiwan TFDA. As of Aug 25th, 2023.*

Encouraging Preliminary Data of ATG-010 (Selinexor) In Combination with Ruxolitinib in Treatment Naïve Myelofibrosis Patients

ANTENGENE

Encouraging Preliminary Data in JAKi Naïve Myelofibrosis

Global Phase I Study Evaluating the Efficacy and Safety of Selinexor

Karyopharm Therapeutics

ATG-010 (selinexor) in combination with **ruxolitinib (JAK1/2 inhibitor)**

2023 ASCO ANNUAL MEETING · EHA EUROPEAN HEMATOLOGY ASSOCIATION

Spleen Responses (SVR35)

Selinexor 60 mg + Ruxolitinib

Efficacy Evaluable Patients	**Week 12:** ▪ **83.3%** achieved SVR35 **(10/12)** **Week 24:** ▪ **91.7%** achieved SVR35 **(11/12)**
Intent-to-Treat Patients	**Week 12:** ▪ **71.4%** achieved SVR35 **(10/14)** **Week 24:** ▪ **78.6%** achieved SVR35 **(11/14)**

Reduction in Total Symptom Scores (TSS50)

Selinexor 60 mg + Ruxolitinib

Efficacy Evaluable Patients	**Week 12:** ▪ **80.0%** achieved TSS50 **(8/10)** **Week 24:** ▪ **77.8%** achieved TSS50 **(7/9)**
Intent-to-treat Patients	**Week 12:** ▪ **66.7%** achieved TSS50 **(8/12)** **Week 24:** ▪ **58.3%** achieved TSS50 **(7/12)**

Karyopharm initiated Phase III trial in June 2023 with 60 mg selinexor as the Recommended Dose in combination with ruxolitinib

Global Registrational Phase I/III Trial – "XPORT-MF-034" Study



Top-line Data Expected in 2025

Encouraging Exploratory Data of ATG-010 (Selinexor) As a Monotherapy in the Maintenance Therapy for TP53 Wild-type Endometrial Cancer Patients

ANTENGENE

Encouraging Updated Exploratory Subgroup Analyses in the "SIENDO" Study*

Global Phase III Study Evaluating the Efficacy and Safety of Selinexor

Karyopharm Therapeutics

ATG-010 (selinexor) as a monotherapy maintenance in **TP53 Wild-type Endometrial Cancer**

ASCO Plenary Series

Median Progression-free Survival (mPFS):

Selinexor (n = 77): 27.4 months (95% CI 13.1 - NR)
Placebo (n = 36): 5.2 months (95% CI 2.0 - 13.1)
HR: 0.42 (95% CI 0.25 - 0.70)
One-sided nominal P-value = 0.0003



Numbers at Risk

Selinexor	77	62	50	47	41	35	27	20	15	12	7	7	4
Placebo	36	22	17	17	12	9	8	7	6	6	4	3	2

Karyopharm's Pivotal Trial- "XPORT-EC-042" Study

TP53 Wild-type Endometrial Cancer

- Primary stage IV or recurrent endometrial cancer
- Received at least 12 weeks of platinum-based therapy +/- immunotherapy
- In partial response (PR) or complete response (CR) to chemotherapy

R 1:1

Selinexor 60 mg orally QW until PD
n = 110

Placebo Weekly
n = 110

Primary Analysis
PFS

Top-line Data Expected in Late 2024 - 2025

Source: Karyopharm Investor Presentation dated August 2nd, 2023
**The "SIENDO" study evaluates selinexor as maintenance therapy for all patients with advanced or recurrent endometrial cancer, and the data being shown is for TP53 wild-type only*

Updated Encouraging Periodic Data of ATG-008 (Onatasertib) in "TORCH-2" Trial

ANTENGENE

Encouraging Periodic Data of ATG-008 (Onatasertib) in Both CPI-naïve and CPI-pre-treated Advanced Cervical Cancer Patient Cohorts

ATG-008 (mTORC1/2i) 15 mg in combination with **toripalimab (PD-1 mAb)**

Overall Response Rate (ORR)

46.4%

Efficacy evaluable population
CPI-Naïve (13/28)

Overall Response Rate (ORR)

26.7%

efficacy evaluable population
CPI-treated (4/15)

Median Progress Free Survival

7.20mths

Efficacy evaluable population
CPI-Naïve

Generally Well Tolerated

Huge Unmet Medical Needs in Advanced Cervical Cancer



Confirm Regulatory Pathway in 2023

Enrollment is ongoing for "TORCH-2" trial, periodic data as of August 23rd, 2023

ATG-008 (Onatasertib): Deep Responses Observed in Cervical Cancer Patients of "TORCH-2" Study

ANTENGENE

Preliminary Efficacy (Onatasertib 15mg, cervical cancer cohort, data as of August 23rd, 2023)

- **31 CPI-naïve patients** received treatment, **28 patients** had at least 1 tumor assessment;
- **17 CPI-pre-treated patients** received treatment; **15 patients** had at least 1 tumor assessment;
- **ORR of CPI-naïve patients cohort is 46.4%** (EE 13/28, unconfirmed); **ORR of CPI pre-treated patients cohort is 26.7%** (EE 4/15, unconfirmed)

CPI-naïve Cervical Cancer Patients



CPI-pre-treated Cervical Cancer Patients



Enrollment is ongoing for "TORCH-2" trial, periodic data as of August 23rd, 2023

ATG-008 (Onatasertib) In Combination with Toripalimab (PD-1 mAb)

Potential Best-in-Class Treatment for 2L+ Cervical Cancer as Demonstrated in "TORCH-2"

ANTENGENE

	ATG 008 (15mg) + Toripalimab (Data from "TORCH-2")	Pembrolizumab (Global Standard of Care)	AK104 (Only CPI Approved by CDE)
Mechanism of Action (MoA)	mTORC 1/2i + PD-1 mAb	PD-1 mAb	PD-1/CTLA-4 BsAb
Number of Patients	28 (EE) (CPI-naïve)	98 (ITT)	100 (FAS, ITT 111)
Prior Treatment Lines	≤2 (50.0%); ≥3 (50.0%)	≤2 (69.4%); ≥3 (30.6%)	≤2 (100%)
PD-L1	N, TPS≥1% (40.0%)	N, CPS≥1 (83.7%)	N
ORR	46.4%;	12.2%	33%
DCR	89.3%	30.6%	52%
PFS (months)	7.20 (4.57, NE)	2.1	3.75
OS (months)	NE	9.4	17.5
Response in AdCa	1/2	1/5	NE

Enrollment is ongoing for "TORCH-2" trial, periodic data as of August 23rd, 2023,

AdCa: Adenocarcinoma

Source: publications & primary research

ANTENGENE

GLOBAL RIGHTS ASSETS

Global Rights Assets: A Clinical Stage Pipeline with Transformational Potentials

Assets	Target *(Modality)*	IND	Phase I	Antengene Rights	Partner
ATG-017 (Tizaterkib)[1]	ERK1/2 *(Small molecule)*	Monotherapy ± nivolumab for R/R Hem/Onc *(ERASER)*	with Bristol Myers Squibb	Global	ANTENGENE
ATG-101[2]	PD-L1/4-1BB *(Bispecific Antibody)*	Monotherapy for Hem/Onc *(PROBE & PROBE-CN)*			
ATG-037[3]	CD73 *(Small molecule)*	Monotherapy ± pembrolizumab for Hem/Onc *(STAMINA)*	with MERCK		
ATG-018	ATR *(Small molecule)*	Monotherapy for Hem/Onc *(ATRIUM)*			
ATG-022	Claudin 18.2 *(ADC)*	Monotherapy for Onc *(CLINCH)*			
ATG-031	CD24 *(Monoclonal Antibody)*	Monotherapy for Hem/Onc *(PERFORM)*			

Antengene Trials

[1] *Licensed from AstraZeneca and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017 (Tizaterkib);*
[2] *Licensed from Origincell and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-101;*
[3] *Licensed from Calithera Biosciences and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-037*
Hem/Onc = hematological malignancies and solid tumors

Global Rights Pipeline Comprised of Clinical Stage Assets with First and/or Best-in-Class Potential

ANTENGENE

	ATG-017 (Tizaterkib)	ATG-101	ATG-037	ATG-018	ATG-022	ATG-031
Target	**ERK1/2**	**PD-L1/4-1BB**	**CD73**	**ATR**	**Claudin 18.2**	**CD24**
Modality	Small Molecule	Bispecific Antibody	Small Molecule	Small Molecule	ADC	Monoclonal Antibody
Differentiation	✓ **Higher potency** and dual IoC and PoA activity with slow off-rate kinetics ✓ Lower efficacious dose with a higher max absorbable dose/dose ratio ✓ **Broad therapeutic potential** (targeting RAS/MAPK pathway) ✓ Multiple **combination** opportunities	✓ PD-L1 cross-linking dependent activation of 4-1BB to avoid unwanted 4-1BB signaling in normal tissue and minimize risk of hepatotoxicity ✓ Demonstrated significant anti-tumor activity in animal models of **resistant tumors as well as those that progressed on anti-PD-1/L1 treatment** ✓ Displayed an **excellent safety profile** in GLP toxicology studies	✓ Orally bioavailable small molecule that completely **overcomes 'hook effect'** common in other anti-CD73 antibodies ✓ **Tissue penetrance not achievable with mAbs** ✓ Promising preclinical efficacy as a monotherapy and strong combination potential	✓ Better ***in vivo* efficacy** compared with benchmark in pre-clinical CDX tumor models ✓ Orally available	✓ **High affinity antibody (pM)**; Strong *in vivo* efficacy pre-clinically in Claudin 18.2 low expression PDX models ✓ Demonstrated an excellent safety profile in GLP toxicology studies	✓ **First in class target** ✓ No clinical competitor ✓ Showed **mono-therapy *in vivo* efficacy and synergy** with chemotherapy, rituximab and CPI
Status	➢ Phase I clinical trial **"ERASER"** ongoing in Australia and US ➢ Monotherapy RP2D achieved ➢ Monotherapy dose expansion and **combo dose escalation with nivolumab initiated enrollment in July 2023**	➢ Phase I clinical trial **"PROBE"** ongoing in Australia and US ➢ Phase I clinical trial **"PROBE-CN"** ongoing in China ➢ Dose escalation studies approaching biologically active dose ➢ US FDA granted an orphan drug designation for the treatment of pancreatic cancer in September 2022	➢ Phase I clinical trial **"STAMINA"** ongoing in Australia, and China for monotherapy and combo with pembrolizumab; currently in dose escalation stage ➢ **13 patients** are undergoing the optional combination dose escalation with pembrolizumab	➢ Phase I clinical trial **"ATRIUM"** ongoing in Australia, currently enrolling patients in the 7th cohort in the dose escalation stage	➢ Phase I clinical trial **"CLINCH"** ongoing in Australia and China, enrolling patients in the 4th cohort ➢ **Partial response detected** at a dose lower than the expected dose range ➢ US FDA granted two consecutive orphan drug designations for the treatment of pancreatic cancer and gastric cancer in May 2023	➢ Phase I clinical trial **"PERFORM"** received IND clearance from the US FDA in May 2023 ➢ The **MD Anderson Cancer Center** will be the leading site for this clinical trial; Initiation of the trial is expected in Q4 2023

ATG-022 (Claudin 18.2 ADC): Phase I "CLINCH" Trial Enrollment Underway

Enrolling Patients with Advanced/Metastatic Solid Tumors

ANTENGENE

Phase I, Open-label, Multi-center, Dose-finding Study Ongoing with Multiple Centers in Australia and the Mainland of China

Phase Ia: Dose Escalation



Primary Objectives: Safety, tolerability. Define MTD and RP2D
Secondary Objectives: Evaluate preliminary efficacy (RECIST 1.1), measure ADA, CLDN18.2 expression
CLDN18.2 Status: No expression requirements

Phase Ib: Dose Expansion



Approximately 120 subjects, depending on the number of cohorts to be expanded.
3 cohorts (pancreatic, gastric, advanced solid tumors)
CLDN18.2+ tumors only. No prior CLDN18.2 agents

First Read out H1 2024

ADA: anti-drug antibody; MTD = maximally tolerated dose, RP2D = recommended Phase 2 dose

ATG-022 (Claudin 18.2 ADC): Preliminary Efficacy in the Phase I "CLINCH" Trial

ANTENGENE

Preliminary Efficacy (as of August 20th, 2023)

- Currently in dose escalation stage, enrolment ongoing
- **7 patients** had at least the first tumor assessment data;
- **1 PR from 1.8mg/kg dose level observed**

Efficacy Summary - Waterfall Plot



Efficacy Summary - Swimmer Plot



ATG-031 (CD24 mAb): Phase I "PERFORM" Trial Expected to Begin in Q4 2023

To Enroll Patients with Advanced Solid Tumors or B-cell Lymphomas

ANTENGENE

Received US FDA IND Clearance in May; Phase I Open Label, Multi-center, Dose-finding Study Starting in the United States

Phase Ia: Dose Escalation

Primary objectives:

Safety, tolerability. Define MTD and RP2D

Secondary objectives:

Evaluate preliminary efficacy and pharmacology

Phase Ib: Dose Expansion

RP2D dose evaluation as monotherapy or combo with chemotherapy or immunotherapy

First Site Initiation in Q4 2023
at the MD Anderson Cancer Center

ADA: anti-drug antibody; MTD = maximally tolerated dose, RP2D = recommended Phase 2 dose

COMMERCIAL OVERVIEW

ANTENGENE

XPOVIO® Commercialization in the Mainland of China and the APAC Regions

ANTENGENE

Regulatory Achievements

Approved in the Mainland of China
December 14th, 2021

Commercial Launch
May 2022

Approved in Australia
March 9th, 2022

Xd Regimen Reimbursement Listing
September 2022

XVd Regimen Reimbursement Listing
June 2023

Approved in South Korea
July 30th, 2021

Expected Reimbursement Listing
Q4 2023

Approved in Taiwan
October 21st, 2022

Expected Reimbursement Listing
Q1 2024

Approved in Singapore
March 1st, 2022

Cancer Drug List Inclusion
August 2023

Approved in Hong Kong
July 17th, 2023

Commercial Launch
August 2023

Expansion into Stage II ASEAN Markets

NDA Submissions

Malaysia | Thailand | Indonesia

Next Wave of Markets

Philippines | Vietnam

XPOVIO® Commercialization



ANTENGENE

COMMERCIALIZATION IN THE MAINLAND OF CHINA

Progress of XPOVIO® in the Mainland of China to Date

ANTENGENE

Laying a Strong Foundation in Preparation for Future Indication Expansion and Commercial Success

Rapid Growth in Revenue Since Commercial Launch

塞利尼索片 20mg
希维奥®

Accumulated Revenue: RMB222.1 Million

(From Commercial Launch in May 2022 to June 30th, 2023)

Treatment Guidelines Recommendation

- ✓ **CSCO/CMDA/CMA/CACA Myeloma Guidelines Recommendation:**
  - the **X-base regimen** is **recommended** for first and multiple relapsed patients
- ✓ **CSCO Lymphoma Guidelines Recommendation:**
  - the **X-base regimen** is **recommended** for 2L+ rrDLBCL patients

Selinexor China Data Publications and Submissions

50+* Selinexor China Data Publications/Submissions in Major Medical Conferences and Medical Journals

Well Established Business Channels**

80+ distributors across the Mainland of China

SPH 上海医药 SHANGHAI PHARMA | 国药集团 SINOPHARM | 华润医药商业 CR PHARMA COMM

Covered **130 DTP pharmacies** across the Mainland of China

上药云健康 | SPS 专业药房 | 邻客·智慧药房 | MEDOFFER 思派大药房 | 德信行大药房 | 圆心大药房

Achieved **60 hospital listings** in **19 provinces**

中国医学科学院血液病医院 INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE | 西京医院 XIJING HOSPITAL

Attained **46 urban-customized commercial health insurance listings (Huiminbao)** covering over **55 million people**

** Includes data generated from real world studies and investigator initiated trials (IITs) in multiple myeloma, lymphoma, acute myeloid leukemia, myelodysplastic syndromes, myelofibrosis, and T-cell acute lymphoblastic leukemia*
*** As of August 11th, 2023*

Antengene Entering into a Commercialization Partnership with Hansoh Pharma on XPOVIO® in the Mainland of China

ANTENGENE

Financial Terms	
Upfront Payment	Antengene will receive **up to RMB200 million** of upfront payments
Milestone Payments	Antengene is eligible to receive **up to RMB535 million** of milestone payments
Recording Revenue	Antengene will continue to **record revenues** from sales of XPOVIO® in the mainland of China
Service Fee	Hansoh Pharma will charge a **service fee** to Antengene

ANTENGENE

Antengene will be responsible for:

1. **Clinical Development**
2. **Regulatory Approvals and Affairs**
3. **Product Supply and Distribution**

翰森製藥 HANSOH PHARMA

Hansoh Pharma will be **exclusively** responsible for **commercialization**

**RMB100 million of upfront payment shall be received upon signing, and pursuant to the Agreement and subject to the terms and conditions thereof, Antengene shall be eligible to receive up to RMB100 million of the remaining upfront payments*

Commercialization Partnership with Hansoh Pharma Aligns with Antengene's Strategic Goals

ANTENGENE

Significance of Collaboration

Recognition on the **commercial potential of XPOVIO®** in the Mainland of China

Maximizes the commercial potential of XPOVIO®, a first/only-in-class XPO1 inhibitor in the Mainland of China by **leveraging Hansoh Pharma's commercial infrastructure**

Improve access of XPOVIO® in the Mainland of China **in preparation for potential NRDL listing** and **expansion of indications**

Ensuring Commercial Success of XPOVIO® in the Mainland of China

Hansoh Pharma Has a Mature Commercialization Platform and Deep Experience in the Commercialzation of Oncology Products in the Mainland of China

ANTENGENE

Mature Commercialization Platform

Thousands
Of Sales Professionals in the Mainland of China

Extensive
Hospital Coverage Across the Mainland of China

翰森製藥 HANSOH PHARMA

Continuously Expanding
DTP Pharmacy Coverage

Proven Oncology Commercial Capability

10+ Oncology Products in Pipeline including;
2 Blockbuster Innovative Drugs and
5+ Hematology Products

阿美乐 甲磺酸阿美替尼

双向优化 豪森昕福 甲磺酸氟马替尼

Oncology Products Account for **>50%** of Hansoh Pharma's Total Revenue

Innovative Drugs Account for **>50%** of Hansoh Pharma's Total Revenue

Extensive Experience in NRDL Negotiations:
6 Innovative Drugs included in the China National Reimbursement Drug List

ANTENGENE

COMMERCIALIZATION IN THE APAC MARKETS

Antengene's APAC Infrastructure Offers a Revenue Generating, Pan-APAC Commercialization Platform Scalable for Growth

ANTENGENE

Scalable Business

Pipeline Assets

Approved and Pan-APAC Commercialized Asset

XPOVIO® (selinexor) 20 mg tablet

Approved in APAC for:

- Multiple Myeloma
- Diffuse Large B-cell Lymphoma

Indication Expansion Opportunity in:

- Myelofibrosis
- Endometrial Cancer

Next Wave of Candidates in the Pipeline

- **ATG-016** (Eltanexor; XPO1i)
- **ATG-008** (Onatasertib; mTORC1/2i)

Multiple In-licensing and CSO Opportunities

- **Multi-sourced platform sourcing opportunities from the US, Europe, China, and APAC**

Geographical Coverage

Stage I Markets



Stage II Markets

NDA Submissions

- Indonesia
- Malaysia
- Thailand

Next Wave of Markets

- Philippines
- Vietnam

Experienced Team

Thomas Karalis
Antengene Head of APAC Regions

Celgene · Bristol Myers Squibb · Lilly · Abbott

30+ Employees Across Functions and Geographies

Strong Track Record of APAC Dedicated Team

Revlimid (lenalidomide) capsules · Vidaza azacitidine for injection · Pomalyst (pomalidomide) capsules 1 · 2 · 3 · 4 mg · IDHIFA (enasidenib) tablets

Future Business Model

- **Portfolio Expansion – Product In-licensing**
- **Geographic Expansion**

Asia Pacific Markets – Executing on XPOVIO® Launch Plans

Excellent Launch Trajectory

Australia

- First multiple myeloma indication (Xd regimen) **reimbursed** on September 1st, 2022
  - XPOVIO® PBS listing achieved in **180 days**
  - Oncology medicines average is **496 days**
- Xd captured **~50% new patient share** of treated penta-refractory multiple myeloma patients
- Reimbursement of XVd regimen secured on **June 1st, 2023**
- Accelerated patient uptake with reimbursement expansion



Other Asia Pacific Markets

- XPOVIO® regulatory approvals in South Korea, Taiwan, Singapore, and Hong Kong
- KOL advocacy and XPOVIO experience:
  - **>250 patients** treated with XPOVIO via pre approval access program
  - Pre-reimbursement **Patient Familiarization Program activated**
- ASEAN markets expansion commencing with **NDA submissions in Thailand, Malaysia & Indonesia Q4 2022**

Asia Pacific Markets 2023 Catalysts

	XVd in MM reimbursement and PBS listing June 1st
	Xd in MM reimbursement Q4 2023 through PE exemption pathway
Taiwan	**XVd** in MM and **X** in DLBCL reimbursement in Q1 2024
Hong Kong	**Xd** in MM regulatory approval - Achieved in July 17th, 2023
	XVd & Xd in MM Cancer Drug List Inclusion: August 1st, 2023

FINANCIAL OVERVIEW

ANTENGENE

2023 1H Financial Highlights (For the Six Months Ended June 30th)

ANTENGENE

Cash and Bank Balances – RMB 1,322 mm

Revenue



Gross Profit



Selling and Distribution Expenses



Research & Development Expenses



Administrative Expenses



Adjusted Loss Excluding Net Foreign Exchange Gain



*Adjusted loss for the period is not defined under the IFRS, it represents the loss for the period excluding the effect brought by equity-settled share-based payment expense.

CLOSING REMARKS

ANTENGENE

2023 is a Catalyst-Rich Year for Antengene

ANTENGENE

Commercialization across China and APAC, with multiple data read outs of clinical stage programs

Selinexor Commercial Launch Across Asia Pacific

- ✓ Reimbursement approval: **Australia** (MM XVd)
- ✓ Reimbursement submission: **South Korea** (MM Xd)
- ✓ Reimbursement submissions: **Taiwan** (MM XVd; DLBCL)
- ✓ XPOVIO® inclusion in the **Singapore Cancer Drug List**
- ✓ Commercial launch: **Hong Kong** (MM Xd)

Clinical Development Progress

- **Confirm regulatory pathway** of **ATG-008** (mTORC1/2i) in advanced cervical cancer
- ✓ **Complete patient enrollment** for **"BENCH" study of ATG-010** (XPO1i) in 2L+ multiple myeloma
- **Preliminary data read out** of **ATG-101** (PD-L1/4-1BB BsAb) "PROBE" trial and "PROBE-CN" trial
- **Preliminary data read out** of **ATG-037** (CD73i) "STAMINA" trial
- **Preliminary data read out** of **ATG-018** (ATRi) "ATRIUM" trial
- **Preliminary data read out** of **ATG-022** (Claudin 18.2 ADC) "CLINCH" trial
- ✓ **First patient dosing: ATG-022** (Claudin 18.2 ADC)
- **First patient dosing: ATG-031** (CD24 mAb)

Multiple Regulatory Filings

- ✓ Selinexor (ATG-010) NDA filing in **Indonesia, Thailand** (MM SVd & Sd; DLBCL), and **Malaysia** (MM SVd & Sd)
- ✓ Selinexor (ATG-010) sNDA filing in **Hong Kong** (MM SVd; DLBCL)
- Selinexor (ATG-010) sNDA filing in **the Mainland of China** (DLBCL)
- Selinexor (ATG-010) sNDA filing in **South Korea** (MM SVd)

✓ = Achieved

ANTENGENE

ANTENGENE CORPORATION LIMITED
(SEHK: 6996.HK)

AUGUST 2023

THANK YOU

TREATING PATIENTS BEYOND BORDERS